EP 7041Alternative Names: EP-7041
Latest Information Update: 04 Oct 2016
At a glance
- Originator eXIthera Pharmaceuticals
- Class Anticoagulants; Antithrombotics; Small molecules
- Mechanism of Action Factor XIa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Thrombosis
Most Recent Events
- 01 Jul 2016 Phase-I clinical trials in Thrombosis (In volunteers) in Australia (IV) (NCT02914353)